Regenerative Medicine
Outline
At the Regenerative Medicine Center, we develop cell therapy technologies and conduct clinical research related to regenerative medicine, transplant medicine, gene therapy, and cancer treatment in accordance with GCTP (Good Gene, Cellular, and Tissue-based Products Manufacturing Practice).We have developed Human Platelet Lysate-induced Antigen Presenting cells (HPL-APC) with higher antigen presentation ability, and investigate the differentiation lineage of APC, such as human dendritic cells. We study the regulation of immune checkpoint molecules and cultured mesenchymal stem cells. We are conducting clinical trials using HPL-APC to clarify the safety and efficacy of cancer vaccine therapy targeting neoantigens. We are promoting international joint research with Kaohsiung Medical University (Taiwan) using neoantigen-compatible T cell receptor (TCR) therapy (TCR-T), contributing to the international standard of individual medical technology.
e-mail: 谤别驳别苍别谤补迟颈惫别【＠】办补苍补锄补飞补-尘别诲.补肠.箩辫
Faculty
Professor and Chair
Assistant Professor
Assistant
Research Achievements
- Koya T, Niida Y, Togi M, Yoshida K, Sakamoto T, Ura H, Togi S, Kato T Jr, Yamada S, Sugiyama H, Koido S, Shimodaira S.The Detection of Immunity against WT1 and SMAD4P130L of EpCAM+ Cancer Cells in Malignant Pleural Effusion. Int J Mol Sci. 23(20):12177, 2022.
- Date I, Koya T, Sakamoto T, Togi M, Kawaguchi H, Watanabe A, Kato T Jr, Shimodaira S. Interferon-α-Induced Dendritic Cells Generated with Human Platelet Lysate Exhibit Elevated Antigen Presenting Ability to Cytotoxic T Lymphocytes. Vaccines (Basel). 9(1):10, 2021.
- Koya T, Date I, Kawaguchi H, Watanabe A, Sakamoto T, Togi M, Kato T Jr, Yoshida K, Kojima S, Yanagisawa R, Koido S, Sugiyama H, Shimodaira S. Dendritic Cells Pre-Pulsed with Wilms' Tumor 1 in Optimized Culture for Cancer Vaccination. Pharmaceutics. 12(4):305, 2020.
- Shimodaira S, Yanagisawa R, Koya T, Hirabayashi K, Higuchi Y, Sakamoto S, Togi M, Kato T Jr, Kobayashi T, Koizumi T, Koido S, and Sugiyama H. In Vivo Administration of Recombinant Human Granulocyte Colony-Stimulating Factor Increases the Immune Effectiveness of Dendritic Cell-Based Cancer Vaccination. Vaccines (Basel). 7(3): 120, 2019.
- Koya T, Yanagisawa R, Higuchi Y, Sano K, Shimodaira S. Interferon-ɑ-inducible dendritic cells matured with OK-432 exhibit TRAIL and Fas ligand pathway-mediated killer activity. Sci Rep. 7:42145. 2017.